High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden

References

• Jönsson B. Cost benefit of treating hypertension. J Hum Hypertens 1994; 12: 65–70
   Google Scholar
• Johannesson M, Le Lorier J. How to assess the economics of hypertension control programmes. J Hum Hypertens 1996; 10: S93–4
   PubMed Web of Science ®Google Scholar
• Johannesson M. The cost-effectiveness of hypertension treatment in Sweden: An analysis of the criteria for intervention and choice of drug treatment. J Hum Hypertens 1999; 10: S23–6
   Google Scholar
• Bøg-Hansen E, Merlo J, Gullberg B, Melander A, Råsstam L, Lindblad U. Survival in patients with hypertension treated in primary care: A population-based follow-up study in the Skaraborg Hypertension and Diabetes Project. Scand J Prim Health Care 2004; 22: 222–7
   PubMed Web of Science ®Google Scholar
• Conn JW. Primary aldosteronism, a new clinical entity. J Lab Clin Med 1955; 5: 3–17
   Google Scholar
• Weinberger MH, Fineberg NS. The diagnosis of primary hyperaldosteronism and separation of two major subtypes. Arch Int Med 1993; 153: 2125–9
   PubMedGoogle Scholar
• Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315–8
   PubMed Web of Science ®Google Scholar
• Anis AY, White WB, Mansoor GA. Hyperaldosteronsim is a common cause of secondary hypertension missed by primary care physicians and associated with normokalemia. Am J Hypertens 1998; 11: 199A
   Google Scholar
• Lim PO, Mac Donald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol 2003; 59: 427–30
   PubMed Web of Science ®Google Scholar
• Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–41
   PubMed Web of Science ®Google Scholar
• Lim PO, Brennan G, Shiels P. Unexpectedly high prevalence of primary hyperaldosteronism in a hypertensive population in Dundee. J Endocrinol 1998; 156: 22
   Google Scholar
• Lim PO, Rodgers P, Cardale K, Watson AD, Mac Donald TM. Potentially high prevalence of primary hyperaldosteronism in a primary-care population. Lancet 1999; 353: 40
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Yamada T, Yukimara Y. A screening test to identify aldosterone-producing adenomas by measuring plasma renin activity: Results in hypertensive patients. Arch Intern Med 1981; 141: 1589–93
   PubMed Web of Science ®Google Scholar
• Montoni VM, Young W, Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: A systematic review of literature. Endocrionol Metab Clin Am 2002; 31: 619–32
   PubMed Web of Science ®Google Scholar
• Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002; 57: 457–65
   PubMed Web of Science ®Google Scholar
• Racine MC, Douville P, Lebel M. Functional tests for primary aldosteronism: Value of Captopril suppression. Curr Hypertens Rep 2002; 4: 245–9
   PubMed Web of Science ®Google Scholar
• Stowasser M, Gordon RD. Primary aldosteronism. Clin Endocrinol Metab 2003; 17: 591–605
   Google Scholar
• Padfield PL. Prevalence and role of raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: A debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol 2003; 59: 422–6
   PubMed Web of Science ®Google Scholar
• Perschel FH, Schemer R, Seiler R, Reincke M, Deinum J, Maser-Gluth C, et al. Rapid screening test for primary hyperaldosteronism: Ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50: 1650–5
   PubMed Web of Science ®Google Scholar
• Prejbisz A, Postula M, Cybulska I, Dobrucki T, Kabat M, Peczkowska M, et al. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism. Kardiol Pol 2003; 58: 17–26
   PubMedGoogle Scholar
• Seiler L, Rump L, Schulte-Mönting J, Slawik M, Borm K, Pavenstädt H, et al. Diagnosis of primary aldosteronism: Value of different screening parameters and influence of antihypertensive drugs. Eur J Endocrinol 2004; 150: 329–37
   PubMed Web of Science ®Google Scholar
• Tanabe A, Naurse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489–94
   PubMed Web of Science ®Google Scholar
• Bravo EL, Foud-Tarazi FM, Tarazi RC. Clinical implications of primary hyperaldosteronism with resistant hypertension. Hypertension 1988; 11: 207–11
   Web of Science ®Google Scholar
• Khan U, Gomez-Sanchez CE. Primary aldosteronism: Evolving concepts in diagnosis and treatment. Curr Opin Endocrinol Diab 2004; 11: 153–7
   Google Scholar
• Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5
   PubMed Web of Science ®Google Scholar
• Plouin PF, Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits?. Eur J Endocrinol 2004; 151: 305–8
   PubMed Web of Science ®Google Scholar
• Stowasser M, Gordon RD. Primary aldosteronism: Careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217: 33–9
   PubMed Web of Science ®Google Scholar
• Young WF, Jr. Minireview: primary aldosteronism: Changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208–13
   PubMed Web of Science ®Google Scholar